SPI-1005

Phase 2Small molecule

SSound Pharmaceuticals, Incorporated

SPI-1005 is one of 59 small molecule programs targeting Meniere disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Meniere DiseaseCompleted

OtotoxicityActive, not recruiting

Hearing LossActive, not recruiting

Meniere DiseasePreclinical

Completed

OtotoxicityPhase 2

Active, not recruiting

Hearing LossPhase 2

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Hearing Loss

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Cymbalta

Alnylam Pharmaceuticals

Approved

1 3

Decadron

AAspen Global Incorporated

Approved

4 4

Plaquenil

Alnylam Pharmaceuticals

Cipro

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

1 7

Kenalog

BBausch Health Americas, Inc.

Approved

—8

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—9

Zonegran

AAzurity Pharmaceuticals

Approved

—10

Osmitrol

BB. Braun Medical Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hearing Loss2 trials

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Unknown status·SSound Pharmaceuticals, Incorporated·Phase 2·NCT01451853·80 enrolled

A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss

Unknown status·SSound Pharmaceuticals, Incorporated·Phase 2·NCT02779192·180 enrolled

Prevention1 trial

Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Completed·SSound Pharmaceuticals, Incorporated·Phase 2·NCT01444846·83 enrolled

Treatment1 trial

SPI-1005 for the Treatment of Patients With Meniere's Disease

Completed·SSound Pharmaceuticals, Incorporated·Phase 2·NCT03325790·149 enrolled

Tics1 trial

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Completed·SSound Pharmaceuticals, Incorporated·Phase 1·NCT01452607·32 enrolled

Meniere disease1 trial

Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease

Completed·SSound Pharmaceuticals, Incorporated·Preclinical·NCT02603081·40 enrolled

1 more indication

Ototoxicity1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity

Completed·SSound Pharmaceuticals, Incorporated·Phase 2·NCT02819856·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for SPI-1005. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SPI-1005 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SPI-1005. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sound Pharmaceuticals, Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSound Pharmaceuticals, Incorporated

SPI-1005

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hearing Loss2 trials

Prevention1 trial

Treatment1 trial

Tics1 trial

Meniere disease1 trial

Ototoxicity1 trial

References

Drug Info

Quick Facts

Related News